InspireMD a Promising Penny Stock

InspireMDInspireMD Inc. (NYSE American: NSPR) is an Israeli medical device company that develops advanced stent technologies for the treatment of coronary and complex vascular diseases. The healthcare industry is expected to expand in the current year, creating an opportunity for InspireMD and its stock to grow.

Elective and non-critical treatments were performed at a lower rate in 2020, due to the high demand on resources created by the Coronavirus Pandemic. With several effective vaccines now available, the healthcare industry is expected to return to normal, with more elective procedures performed. InspireMD could benefit with its offering of stent devices designed for acute myocardial infarction and saphenous vein graft coronary interventions.

Stock in InspireMD has rallied over the last week, with the price up by 15.47% over five trading days when the markets closed yesterday. This growth is pushing the stock towards its estimated target of $1.05. For its potential short-term growth and the long-term prospects of InspireMD as a medical device supplier, this is one of the best bargain alternative stocks to consider in March.

Key Data:

  • 1 Year Price Growth: 71%
  • YTD Price Growth: 41%
  • 3 Month Price Growth: 99%

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.

 

The reports, research and newsletter are based on current and historical market data, as well as publicly available financial data.They are intended to be a starting point for investors. They do not provide every material fact about a company or industry, nor are they recommendations to buy or sell. The writers and the company make no warranties or representations as to the accuracy of these reports.   You should NOT rely solely upon the information or opinions read in the content. Rather, you should use the content as a starting point for doing independent research on the independent analysis and trading methods in the content. The content is impersonal and does not provide individualized advice or recommendations for any specific reader or individual portfolio. By accessing this website you have agreed to our disclaimers and privacy policy.

 

You May Also Like

About the Author: Writocity